Key findings relevant to injection site safety: Injection site reactions were not significantly higher in retatrutide groups compared to placebo The most common injection site reactions were transient redness and mild discomfort No participants discontinued due to injection site reactions The overall safety profile was consistent with other GLP-1 receptor agonists The more recent TRIUMPH-4 phase 3 trial confirmed these safety findings in a larger population
The uncertainty itself is not ideal for planning
Sakurabayashi, T., Miyazaki, S., Yuasa, Y., Sakai, S., Suzuki, M., Takahashi, S., and Hirasawa, Y
At present, the lowest reported starting price is around 1,290 per month for vial-based semaglutide from Natco and Eris
But the primary reason people are using these medications that we see talked about so often is weight loss